Abstract
Peptidomimetic drugs are a rapidly growing field for treatment of disease. With the current screening-based approach yielding fewer and fewer drug candidates, peptide drugs appear to be the next frontier of disease treatment. Still, the issues of structural stability and half-life exist for peptides due to the vast number of proteases in the cell. We combine computational structure-guided design and solution NMR techniques including 19F NMR to rapidly design and screen peptide inhibitors for both protein:protein interactions (PPI) and protein:nucleotide interactions (PNI). Structural stability is greatly increased by utilizing D-amino acids at alpha helix termini, which also may enhance metabolic half-life. Both PPI and PNI interfering peptides demonstrate promising binding activity to target sites.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
